Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer: early-phase trial registry
162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #14 of 28,707 conditions by registered trial count.
394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count
Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.
Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.
Enrollment posture brief
Registry condition colorectal-cancer
OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22
Volume-matched condition peers
Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)
Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer is recruiting above its size-band peers.
162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer enrolment sits around 132 participants.
Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.
-
Colorectal Cancer research is mostly interventional.
323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
394 total, page 4 of 8
GCC19CART for Patients With Metastatic Colorectal Cancer
Lyell Immunopharma
NCT05319314
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05343013
Evaluation of SINGLE PORT (SP) Robotic Technology in Colorectal Surgery
University of California, Davis
NCT05321134
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
NCT06300463
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
NCT04920032
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT07136077
Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses
GI Windows
NCT07276529
LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
Masonic Cancer Center, University of Minnesota
NCT07153016
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
M.D. Anderson Cancer Center
NCT06617858
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
Massachusetts General Hospital
NCT05524428
The Northern-European Initiative on Colorectal Cancer
Oslo University Hospital
NCT00883792
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)
VA Office of Research and Development
NCT01239082
Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening
Abramson Cancer Center at Penn Medicine
NCT05693649
PROSPR Project 1: Identifying and Tracking Personalized CRC Screening Regimens for Patients in Clinical Settings
University of Texas Southwestern Medical Center
NCT03705897
The Engaging Primary Care in Cancer Survivorship (EPICS) Study
Kaiser Permanente
NCT04745754
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Exact Sciences Corporation
NCT05210283
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Exelixis
NCT05425940
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Canadian Cancer Trials Group
NCT00819208
The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
Louisiana State University Health Sciences Center Shreveport
NCT04313114
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
Improving Care After Inherited Cancer Testing
Vanderbilt-Ingram Cancer Center
NCT04763915
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT05029882
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech
NCT04449874
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Invitae Corporation
NCT05219734
Colorectal Cancer Screening in Cystic Fibrosis
University of Washington, the Collaborative Health Studies Coordinating Center
NCT05362344
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT03845166
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
Merck Sharp & Dohme
NCT04895722
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
Memorial Sloan Kettering Cancer Center
NCT01815359
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT06328738
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT00335816
CRC Detection Reliable Assessment With Blood
New Day Diagnostics
NCT05551052
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT04868877
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
Massachusetts General Hospital
NCT02394769
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
Massachusetts General Hospital
NCT05056896
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Elicio Therapeutics
NCT05726864
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
Complement Theory
NCT06397651
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Dana-Farber Cancer Institute
NCT05327452
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
SafeHeal Diverting Ileostomy Pivotal Study
SafeHeal
NCT06152276
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT04902872
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT04440735
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
Charles Drew University of Medicine and Science
NCT05765214
The Active After Cancer Trial (AACT)
Dana-Farber Cancer Institute
NCT00548236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 132 |
| Phase 2 | 69 |
| Phase 3 | 10 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colorectal Cancer page
394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 162 Colorectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Colorectal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.